Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Laboratory Investigation

Interferon-α Promotes the Anti-Proliferative Effect of Gefitinib (ZD1839) on Human Colon Cancer Cell Lines

Yang J.-L.a, c · Qu X.-J.d · Russell P.J.a · Goldstein D.b

Author affiliations

aOncology Research Centre and bDepartment of Medical Oncology, Prince of Wales Hospital, and cDepartment of Surgery and Surgical Oncological Research Group, Prince of Wales Clinical School, University of New South Wales, Sydney, Australia; dDepartment of Pharmacology, College of Pharmacy, Shandong University, Jinan, People’s Republic of China

Related Articles for ""

Oncology 2005;69:224–238

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Laboratory Investigation

Received: January 20, 2005
Accepted: May 04, 2005
Published online: October 10, 2005
Issue release date: September 2005

Number of Print Pages: 15
Number of Figures: 8
Number of Tables: 3

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: https://www.karger.com/OCL

Abstract

Objective: Interferon-α (IFNα) treatment is associated with up-regulation of epidermal growth factor receptor (HER1/EGFR) expression and marked growth inhibition of colon cancer cell lines in vitro.We aimed to determine the effect of combining IFNα and gefitinib on colon cancer cell line growth. Methods: A panel of nine colon cancer cell lines were characterised for expression of HER1/EGFR and then treated with gefitinib alone, or IFNα alone, or IFNα plus gefitinib, following a pre-treatment using vehicle or IFNα. Crystal violet staining and flow cytometry were used to assess cell proliferation and expression of HER1/EGFR. The indexes and statistical assays were used to evaluate significant differences between treatment groups against vehicle control. Results: All cell lines except SW620 were HER1/EGFR positive. IFNα treatment was associated with significant up-regulation of cell surface HER1/EGFR expression in all HER1/EGFR-positive cell lines except KM12SM. Concurrent treatment with IFNα and gefitinib, or IFNα pre-treatment followed by gefitinib, or IFNα pre-treatment followed by a combination of IFNα plus gefitinib, additively or supra-additively/synergistically enhanced the sensitivity of the seven HER1/EGFR-up-regulated cell lines. Conclusion: IFNα improves the anti-proliferative effect of EGFR inhibition in colorectal cancer cell lines. This approach may have clinical implications for improving treatment based on targeting of HER1/EGFR.

© 2005 S. Karger AG, Basel


References

  1. Elledge RM, Fuqua SAW: Estrogen and progesterone receptors; in Harris JR, Lippman ME, Morrow M, Osborne CK (eds): Diseases of the Breast, ed 2. Philadelphia, Lippincott, Williams & Wilkins, 2000, p 471.
  2. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR: Pathological findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990;8:103–112.
  3. Cohen MH, Williams GA, Stridhara R, Chen G, Pazdur R: FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003;8:303–306.
  4. Supramanian R, Smith DP, Coates MS: Survival from cancer in New South Wales in 1980 to 1995. Sydney, NSW Cancer Council, 1998.
  5. Wells A: Molecules in focus, EGFR receptor. Int J Biochem Cell Biol 1999;31:637–643.
  6. Perry JE, Grossman ME, Tindall DJ: Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line. Prostate 1998;35:117–124.
  7. Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241–250.
  8. Grunwald V, Hidlago M: Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 2003;95:851–867.
  9. Ge H, Gong X, Tang CK: Evidence of high incidence of EGFR VIII expression and coexpression with EGFR in human invasive breast cancer by laser capture micro-dissection and immunohistochemical analysis. Int J Cancer 2002;98:357–361.
  10. Rubin Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD, Tweardy DJ: Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824–832.
  11. Blackledge G, Averbuch S: Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer 2004;90:566–572.
  12. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237–2246.
  13. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149–2158.
  14. Grunwald V, Hidalgo M: Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774). Adv Exp Med Biol 2003;532:235–246.
  15. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238–3247.
  16. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337–345.
  17. Rothenberg ML, Lafleur B, Washington MK, Levy DE, Morgan-Meadows SL, Ramanathan RK, Berlin JD, Benson AIB, Coffey RJ: Changes in epidermal growth factor receptor signaling in serum and tumor biopsies obtained from patients with progressive metastatic colorectal cancer (MCRC) treated with gefitinib (ZD1839): an Eastern Cooperative Oncology Group study (abstract 3000). Proc Am Soc Clin Oncol 2004;23:195.
  18. Oza AM, Townsley CA, Siu LL, Major P, Hedley D, Tsao M, Gill B, Pond GR, Dancey J, Moore MJ: Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003;22:196.
  19. Bos M, Medelsohn J, Kim YM, Albanell J, Fry DW, Baselga J: PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res 1997;3:2099–2106.
  20. Hambek M, Solbach C, Schuerch HG, Roller M, Stegmueller M, Sterner-Kock A, Kiefer J, Knecht R: Tumor necrosis factor α sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy. Cancer Res 2001;61:1045–1049.
  21. Grünwald V, Hidalgo M: Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Nat Cancer Inst 2003;95:851–867.
  22. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:1–11.
    External Resources
  23. Yang JL, Qu XJ, Russell PJ, Goldstein D: Regulation of epidermal growth factor receptor in human colon cancer cell lines by interferon alpha. Gut 2004;53:123–129.
  24. Goldstein D, Bushmeyer SM, Witt PL, Jordan VC, Borden EC: Effects of type I and II interferons on cultured human breast cells: interaction with estrogen receptors and with tamoxifen. Cancer Res 1989;49:2698–2702.
  25. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27–55.
  26. Robinson SP, Goldstein D, Witt PL, Borden EC, Jordan VC: Inhibition of hormone-dependent and independent breast cancer cell growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon-alpha 2. Breast Cancer Res Treat 1990;5:95–101.
  27. Yang JL, Qu XJ, Russell PJ, Goldstein D: Interferon-alpha enhances the anti-proliferative effect of gefitinib (OSI-774) on human colon cancer cell lines (abstract 4650). 95th Annu Meet Proc Am Assoc Cancer Res, 2004.
  28. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR, Tortora G: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001;7:1459–1465.
  29. Chill JH, Nivasch R, Levy R, Alback S, Schreiber G, Anglister J: The human interferon receptor: NMR-based modeling, mapping of the IFN-alpha 2 binding site, and observed ligand-induced tightening. Biochemistry 2002;41:3575–3585.
  30. Leaman DW, Pisharody S, Flicking TW, Commane MA, Schlessinger J, Kerr IM, Levy DE, Stark GR: Roles of JAKs in activation of STATs and stimulation of c-fos gene expression by epidermal growth factor. Mol Cell Biol 1996;16:369–375.
  31. Rane SG, Reddy EP: Janus kinases: components of multiple signaling pathways. Oncogene 2000;19:5662–5679.
  32. Uddin S, Lekmine F, Sassano A, Rui H, Fish EN, Platanias LC: Role of Stat5 in type I interferon-signaling and transcriptional regulation. Biochem Biophys Res Commun 2003;308:325–330.
  33. Chan KS, Carbajal S, Kiguchi K, Clifford J, Sano S, DiGiovanni J: Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis. Cancer Res 2004;64:2382–2389.
  34. Ueno H, Sasaki K, Miyagawa K, Honda H, Mitani K, Yazaki Y, Hirai H: Antisense repression of proto-oncogene c-Cbl enhances activation of the JAK-STAT pathway but not the Ras pathway in epidermal growth factor receptor signaling. J Biol Chem 1997;272:8739–8743.
  35. Kloth MT, Catling AD, Silva CM: Novel activation of STAT5b in response to epidermal growth factor. J Biol Chem 2002;277:8693–8701.
  36. Caraglia M, Tagliaferri P, Marra M, Giuberti G, Budillon A, Gennaro ED, Pepe S, Vitale G, Improta S, Tassone P, Venuta S, Bianco AR, Abbruzzese A: EGF activates an inducible survival response via the RAS-Erk-1/2 pathway to counteract interferon-mediated apoptosis in epidermoid cancer cells. Cell Death Differ 2003;10:218–229.
  37. Klampfer L, Huang J, Corner G, Mariadason J, Arango D, Sasazuki T, Shirasawa S, Augenlicht L: Oncogenic Ki-ras inhibits the expression of interferon-responsive genes through inhibition of STAT1 and STAT2 expression. J Biol Chem 2003;278:46278–46287.
  38. Nagano K, Masters JR, Akpan A, Yang A, Corless S, Wood C, Hastie C, Zvelebil M, Cramer R, Naaby-Hansen S: Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons. Oncogene 2004;23:1693–1703.
  39. Romerio F, Zella D: MEK and ERK inhibitors enhance the anti-proliferative effect of interferon-α2b. FASEB J 2002;16:1680–1682.
  40. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786–792.
  41. Gazdar AF, Shigematsu H, Herz J, Minna JD: Mutations and addiction to EGFR: the Achilles ‘heal’ of lung cancers. Trends Mol Med 2004;10:481–486.
  42. BarberTD,VogelsteinB,KinzlerKW,VelculescuVE: Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004;351:2883.
  43. Cappuzzo F, Magrini E, Ceresoli GL: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2004;96:1133–1141.
  44. Han SW, Hwang PG, Chung DH, Kim DW, et al: Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer 2005;113:109–115.
  45. Amann J, Kalvankrishna S, Massion PP: Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005;65:226–235.
  46. Fish EN, Ghislain J, Trogadis J, Stevens JK: Inhibitory effects of alpha-interferon on epidermal growth factor-mediated receptor-dependent events. Cancer Res 1993;53:5148–5157.
  47. Rubinstein YR, Proctor KN, Bergel M, Murphy B, Johnson AC: Interferon regulatory factor-1 is a major regulator of epidermal growth factor receptor gene expression. FEBS Lett 1998;431:268–272.
  48. Budillon A, Tagliaferri P, Caraglia M, Torrisi MR, Normanno N, Iacobelli S, Palmieri G, Stoppelli MP, Frati L, Bianco AR: Upregulation of epidermal growth factor receptor induced by α-interferon in human epidermoid cancer cells. Cancer Res 1991;51:1294–1299.
  49. Caraglia M, Abbruzzese A, Leardi A, Pepe S, Budillon A, Baldassare G, Selleri C, Lorenzo SD, Fabbrocini A, Giuberti G, Vitale G, Lupoli G, Bianco AR, Tagliaferri P: Interferon-alpha induces apoptosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor. Cell Death Differ 1999;6:773–780.
  50. Caraglia M, Tagliaferri P, Correale P, Genua G, Pinto A, Del Vecchio S, Esposito G, Bianco AR: Cytosine arabinoside increases the binding of 125I-labelled epidermal growth factor and 125I-transferrin and enhances the in vitro targeting of human tumour cells with anti-(growth factor receptor) mAb. Cancer Immunol Immunother 1993;37:150–156.
  51. Caraglia M, Pinto A, Correale P, Zagonel V, Genua G, Leardi A, Pepe S, Bianco AR, Tagliaferri P: 5-Aza-2′-deoxycytidine induces growth inhibition and upregulation of epidermal growth factor receptor on human epithelial cancer cells. Ann Oncol1994;5:269–276.
  52. Qu XJ, Yang JL, Russell PJ, Goldstein D: Changes in epidermal growth factor receptor expression in human bladder cancer cell lines following interferon-α treatment. J Urol 2004;172:733–738.
  53. Eisenkraft BL, Nanus DM, Albino AP, Pfeffer LM: α-Interferon down-regulates epidermal growth factor receptors on renal carcinoma cells: relation to cellular responsiveness to the antiproliferative action of α-interferon. Cancer Res 1991;51:5881–5887.
  54. She QB, Solit D, Basso A, Moasser M: Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akr pathway signaling. Clin Cancer Res 2003;9:4340–4346.
  55. Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen M, Tsurutani J, Dennis PA, Mills GB: Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003;22:2812–2822.
  56. Panaretakis T, Pokrovskaja K, Shoshan MC, Grander D: Interferon-α-induced apoptosis in U266 cells is associated with activation of the proapoptotic Bcl-2 family members Bak and Bax. Oncogene 2003;22:4543–4556.

Article / Publication Details

First-Page Preview
Abstract of Laboratory Investigation

Received: January 20, 2005
Accepted: May 04, 2005
Published online: October 10, 2005
Issue release date: September 2005

Number of Print Pages: 15
Number of Figures: 8
Number of Tables: 3

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: https://www.karger.com/OCL


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.